Erasca shares rise as company narrows timing for key ERAS-0015 Phase 1 data readout

Erasca, Inc. (ERAS) is up 5.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is a newly filed update that narrows the expected timing for Erasca’s upcoming Phase 1 monotherapy data readout for ERAS-0015 to no later than mid-May 2026. For a clinical-stage oncology company, pulling forward (or tightening) a major data window can increase near-term expectations and drive speculative buying ahead of the readout.

Details:

A Form 8-K filed on April 21, 2026 narrowed the anticipated Phase 1 monotherapy data readout timing for ERAS-0015 to no later than mid-May 2026, versus prior guidance of the first half of 2026.

The update references results expected from two Phase 1 studies of ERAS-0015: the AURORAS-1 trial and the JYP0015M101 trial.

ERAS-0015 is described as a pan-RAS molecular glue being evaluated in patients with RAS-mutant advanced solid tumors, making the upcoming readout a key near-term milestone for the company’s RAS-focused pipeline.

This could also be amplified by positioning into a defined near-term “event date,” which often increases volatility for biotech names ahead of clinical updates.

Sources:

U.S. Securities and Exchange Commission, Erasca Investor Relations, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ERAS Insider Trading Activity

$ERAS insiders have traded $ERAS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $ERAS stock by insiders over the last 6 months:

EBUN GARNER (Chief Legal Officer) has made 0 purchases and 2 sales selling 200,000 shares for an estimated $1,982,812.
SHANNON MORRIS (Chief Medical Officer) sold 20,000 shares for an estimated $300,760

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive ERAS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ERAS Hedge Fund Activity

We have seen 77 institutional investors add shares of $ERAS stock to their portfolio, and 69 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 15,445,081 shares (-76.3%) from their portfolio in Q4 2025, for an estimated $57,455,701
LOGOS GLOBAL MANAGEMENT LP removed 2,150,000 shares (-14.2%) from their portfolio in Q4 2025, for an estimated $7,998,000
STATE STREET CORP added 2,145,386 shares (+53.2%) to their portfolio in Q4 2025, for an estimated $7,980,835
EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,490,967 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,546,397
SIO CAPITAL MANAGEMENT, LLC removed 1,369,748 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,095,462
ROCK SPRINGS CAPITAL MANAGEMENT LP added 951,710 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,540,361
IKARIAN CAPITAL, LLC added 735,396 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,735,673

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ERAS Analyst Ratings

Wall Street analysts have issued reports on $ERAS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 11/14/2025

To track analyst ratings and price targets for $ERAS, check out Quiver Quantitative's $ERAS forecast page.

$ERAS Price Targets

Multiple analysts have issued price targets for $ERAS recently. We have seen 8 analysts offer price targets for $ERAS in the last 6 months, with a median target of $19.5.

Here are some recent targets:

Anupam Rama from JP Morgan set a target price of $25.0 on 03/18/2026
Michael Schmidt from Guggenheim set a target price of $20.0 on 03/16/2026
Andres Y. Maldonado from HC Wainwright & Co. set a target price of $20.0 on 03/13/2026
Joseph Catanzaro from Mizuho set a target price of $19.0 on 03/13/2026
Kelsey Goodwin from Piper Sandler set a target price of $18.0 on 03/13/2026
Kaveri Pohlman from Clear Street set a target price of $20.0 on 03/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.